Assessment of histological remission in ulcerative colitis: discrepancies between daily practice and expert opinion.

Assessment of histological remission in ulcerative colitis: discrepancies between daily practice and expert opinion. J Crohns Colitis. 2017 Dec 12;: Authors: Römkens TEH, Kranenburg P, van Tilburg A, Bronkhorst C, Nagtegaal ID, Drenth JPH, Hoentjen F Abstract Background and aims: Histological remission (HR) is a potential treatment target in ulcerative colitis (UC). Limited ‘real world ‘ data is available on reliability of histological scoring when assessing minimal histological inflammation. The aim of our study was to investigate the reliability of UC histological scores in colonic biopsies showing mucosal healing (MH)…

Read More

Prepouch Ileitis After Ileal Pouch-anal Anastomosis: Patterns of Presentation and Risk Factors for Failure of Treatment.

Prepouch Ileitis After Ileal Pouch-anal Anastomosis: Patterns of Presentation and Risk Factors for Failure of Treatment. J Crohns Colitis. 2017 Oct 09;: Authors: Rottoli M, Vallicelli C, Bigonzi E, Gionchetti P, Rizzello F, Di Simone MP, Poggioli G Abstract Background and Aims: There is a lack in the literature about prepouch ileitis [PI], in particular regarding risk factors associated with failure of the medical treatment. Aim of the study is to analyse the characteristics of PI patients and to compare those who required surgery with those who were successfully treated…

Read More

Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn’s disease: a population-based Danish cohort study.

Related Articles Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn’s disease: a population-based Danish cohort study. Aliment Pharmacol Ther. 2017 Dec 14;: Authors: Singh S, Andersen NN, Andersson M, Loftus EV, Jess T Abstract BACKGROUND: There are conflicting data on comparative effectiveness of adalimumab and infliximab in patients with Crohn’s disease (CD). AIMS: To compare the effectiveness and safety of adalimumab and infliximab in biologic-naïve patients with CD, in a nationwide register-based propensity score-matched cohort study in Denmark. METHODS: A total of 2908 Danish adults with CD…

Read More

Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases.

Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases. Am J Gastroenterol. 2017 Dec 12;: Authors: Govani SM, Noureldin M, Higgins PDR, Heisler M, Saini SD, Stidham RW, Waljee JF, Waljee AK Abstract OBJECTIVES: In patients with inflammatory bowel disease (IBD) using biological therapy, non-adherence leads to anti-drug antibody formation and reduced effectiveness. Little is known about the optimal level of adherence in IBD patients on biologic therapy. We aimed to identify the association between adherence and disease flare and determine an optimal level of…

Read More

The efficacy of home telemonitoring versus conventional follow-up: a randomised controlled trial among teenagers with inflammatory bowel disease.

The efficacy of home telemonitoring versus conventional follow-up: a randomised controlled trial among teenagers with inflammatory bowel disease. J Crohns Colitis. 2017 Dec 08;: Authors: Heida A, Dijkstra A, Muller Kobold A, Rossen J, Kindermann A, Kokke F, de Meij T, Norbruis O, Weersma R, Wessels M, Hummel T, Escher H, van Wering H, Hendriks D, Mearin L, Groen H, Verkade H, van Rheenen P Abstract Background and aims: Conventional follow-up of teenagers with inflammatory bowel diseases (IBD) is done during scheduled outpatient visits regardless of how well the patient…

Read More

Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing. Authors’ reply.

Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing. Authors’ reply. Aliment Pharmacol Ther. 2018 Jan;47(1):130-131 Authors: Broekman MMTJ, Wanten GJ, de Jong DJ PMID: 29226420 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29226420?dopt=Abstract

Read More

The long-term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection.

The long-term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2017 Dec 11;: Authors: Jalanka J, Hillamaa A, Satokari R, Mattila E, Anttila VJ, Arkkila P Abstract BACKGROUND: Faecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection. In short-term the treatment has been shown to be safe, however, there are no large, long-term follow-up studies looking into the potential adverse effects. AIM: To analyse the long-term effect of FMT treatment in patients with…

Read More

Vedolizumab-associated pancreatitis in paediatric ulcerative colitis – functional selectivity of the α4β7integrin and MAdCAM-1 pathway?

Vedolizumab-associated pancreatitis in paediatric ulcerative colitis – functional selectivity of the α4β7integrin and MAdCAM-1 pathway? J Crohns Colitis. 2017 Dec 08;: Authors: Lopez RN, Gupta N, Lemberg DA PMID: 29228226 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29228226?dopt=Abstract

Read More
<< Go Back